Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4337-4345

  Parent, Romain ^a   Kolippakkam, Deepak ^a   Booth, Garrett ^a   Beretta, Laura ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CCAAT ENHANCER BINDING PROTEIN ALPHA; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RAPAMYCIN; RETINOID X RECEPTOR BETA; TUMOR NECROSIS FACTOR;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; HOMEOSTASIS; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE; DOWN-REGULATION; HEPATOCYTES; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; POLYRIBOSOMES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA; SIROLIMUS; TRANSFECTION;

EID: 34249304441     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3640     Document Type: Article

References (46)

1. Sala M, Forner A, Varela M. Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver His 2005;25:171-80.
2. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver His 2005;25:212-25.
3. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9.
4. Horie Y, Suzuki A, Kataoka E, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-83.
5. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
6. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 2001;98:10320-5.
7. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996;15:658-64.
8. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998;95:1432-7.
9. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004;10:8421-5.
10. Parent R, Marion MJ, Furio L, Trepo C, Petit MA. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 2004;126:1147-56.
11. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002;99:15655-60.
12. Troadec MB, Glaise D, Lamtrault G, et al. Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line. Genomics 2006;87:93-103.
13. Grolleau A, Bowman J, Pradet-Balade B, et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem 2002;277:22175-84.
14. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-13.
15. Matthews VB, Yeoh GC. Liver stem cells. IUBMB Life 2005;57:549-53.
16. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis 2003;23:385-96.
17. Fouassier L, Duan CY, Feranchak AP, et al. Ezrinradixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology 2001;33:166-76.
18. Edmondson HA, Steiner PE. Primary carcinoma of the liver; a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
19. Song K, Wang H, Krebs TL, Danielpour D, Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J 2006;25:58-69.
20. Rodrigues CM, Steer CJ. Fooling the Fas ligand in death. Hepatology 2006;44:314-7.
21. Kim EJ, Park JI, Nelkin BD. IF116 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem 2005;280:4913-20.
22. Fujiuchi N, Aglipay JA, Ohtsuka T, et al. Requirement of IF116 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem 2004;279:20339-44.
23. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 2002;277:575-85.
24. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
25. Haouzi D, Baghdiguian S, Granier G, Travo P, Mangeat P, Hibner U. Three-dimensional polarization sensitizes hepatocytes to Fas/CD95 apoptotic signalling. J Cell Sci 2005;118:2763-73.
26. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998;273:29577-85.
27. Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor α. Alcohol 2004;34:35-8.
28. Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor a during hepatitis C virus infection. Gastroenterology 2005;128:334-42.
29. Oliver WR, Jr., Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001;98:5306-11.
30. Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor 6 induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 2003;100:15924-9.
31. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor fi activates fat metabolism to prevent obesity. Cell 2003;113:159-70.
32. Lee CH, Olson P, Hevener A, et al. PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006;103:3444-9.
33. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 2004;10:481-3.
34. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-9.
35. Shiota G. Loss of function of retinoic acid in liver leads to steatohepatitis and liver tumor: a NASH animal model. Hepatol Res 2005;33:155-60.
36. Hayashi Y, Wang W, Ninomiya T, Nagano H, Ohta K, Itoh H. Liver enriched transcription factors and differentiation of hepatocellular carcinoma. Mol Pathol 1999;52:19-24.
37. Birkenmeier EH, Gwynn B, Howard S, et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989;3:1146-56.
38. Watkins PJ, Condreay JP, Huber BE, Jacobs SJ, Adams DJ. Impaired proliferation and tumorigenicity induced by CCAAT/enhancer-binding protein. Cancer Res 1996;56:1063-7.
39. Tan EH, Hooi SC, Laban M, et al. CCAAT/enhancer binding protein α knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res 2005;65:10330-7.
40. Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M. Down-regulated expression of the CCAAT/enhancer binding protein a and P. genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res 2003;23:351-4.
41. Flodby P, Barlow C, Kylefjord H, Ahrlund-Richter L, Xanthopoulos KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein α. J Biol Chem 1996;271:24753-60.
42. Wang ND, Finegold MJ, Bradley A, et al. Impaired energy homeostasis in C/EBPα knockout mice. Science 1995;269:1108-12.
43. Yang J, Croniger CM, Lekstrom-Himes J, et al. Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein α. J Biol Chem 2005;280:38689-99.
44. Son G, Hirano T, Seki E, et al. Blockage of HGF/c-Met system by gene therapy (adenovlrus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol 2006;45:688-95.
45. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13.
46. Uematsu S, Higashi T, Nouso K, et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:583-8.